LetterReply
Drs. Cron and Chatham reply
Randy Q. Cron and W. Winn Chatham
The Journal of Rheumatology June 2020, jrheum.200744; DOI: https://doi.org/10.3899/jrheum.200744
Randy Q. Cron
From the University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology; Department of Medicine, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Address correspondence to Dr. R.Q. Cron, Children’s of Alabama, Division of Rheumatology, 1600 7th Ave. S., CPPN, suite G10, Birmingham, Alabama 35233-1711, USA. E-mail: rcron@peds.uab.edu. Drs. Cron and Chatham are co-principal investigators on an investigator-initiated clinical trial to study interleukin 1 blockade in treating secondary hemophagocytic lymphohistiocytosis in children and adults. The trial is funded by Swedish Orphan Biovitrum Inc. (SOBI; ClinicalTrials.gov: ), which manufactures anakinra. Dr. Cron serves as a consultant to SOBI. Dr. Chatham has served as a consultant to SOBI.
W. Winn Chatham
From the University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology; Department of Medicine, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Address correspondence to Dr. R.Q. Cron, Children’s of Alabama, Division of Rheumatology, 1600 7th Ave. S., CPPN, suite G10, Birmingham, Alabama 35233-1711, USA. E-mail: rcron@peds.uab.edu. Drs. Cron and Chatham are co-principal investigators on an investigator-initiated clinical trial to study interleukin 1 blockade in treating secondary hemophagocytic lymphohistiocytosis in children and adults. The trial is funded by Swedish Orphan Biovitrum Inc. (SOBI; ClinicalTrials.gov: ), which manufactures anakinra. Dr. Cron serves as a consultant to SOBI. Dr. Chatham has served as a consultant to SOBI.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Drs. Cron and Chatham reply
Randy Q. Cron, W. Winn Chatham
The Journal of Rheumatology Jun 2020, jrheum.200744; DOI: 10.3899/jrheum.200744